E-GEOD-32657 - Transcriptome and proteome analysis of tyrosine kinase treated canine mast cell tumour cells identifies potentially KIT signalling-dependent genes

Released on 24 July 2012, last updated on 6 August 2012
Canis lupus familiaris
Samples (12)
Array (1)
Protocols (6)
Canine mast cell tumour proliferation depends to a large extent on the activity of KIT, a tyrosine kinase receptor. Inhibitors of the KIT tyrosine kinase have recently been introduced and successfully applied as a therapeutic agent for this tumour type. However, little is known on the downstream target genes of this signalling pathway and molecular changes after inhibition. Transcriptome analysis of the canine mast cell tumour cell line C2 treated for up to 72 hours with the tyrosine kinase inhibitor masitinib identified significant changes in the expression levels of approximately 3500 genes representing 16% of the canine genome. Approximately 40% of these genes had increased mRNA expression levels including genes associated with the pro-proliferative pathways of B- and T-cell receptors, chemokine receptors, steroid hormone receptors and EPO-, RAS and MAP kinase signalling. Proteome analysis of C2 cells treated for 72 hours identified 24 proteins with changed expression levels, most of which being involved in gene transcription, e.g. EIA3, EIA4, TARDBP, protein folding, e.g. HSP90, UCHL3, PDIA3 and protection from oxidative stress, GSTT3, SELENBP1. Transcriptome and proteome analysis of neoplastic canine mast cells treated with masitinib confirmed the strong important and complex role of KIT in these cells. Approximately 16% of the total canine genome and thus the majority of the active genes were significantly transcriptionally regulated. Most of these changes were associated with reduced proliferation and metabolism of treated cells. Interestingly, several pro-proliferative pathways were up-regulated which may represent attempts of masitinib treated cells to activate alternative pro-proliferative pathways. These pathways may contain hypothetical targets for a combination therapy with masitinib to further improve its therapeutic effect. The present study aimed at identifying the transcriptional and translational responses of neoplastic canine mast cells to the tyrosine kinase inhibitor masitinib. To this end, C2 cells, a cell line with a tandem duplication in the juxtamembrane unit and thus constitutively activated KIT, were treated with masitinib and changes in the global mRNA and protein expression levels were characterized.
Experiment type
transcription profiling by array 
Achim D Gruber, Angelika Bondzio, Anja Meyer, Chris Weise, Dido Lenze, Michael Hummel, Patricia Schlieben, Ralf Einspanier, Robert Klopfleisch
Investigation descriptionE-GEOD-32657.idf.txt
Sample and data relationshipE-GEOD-32657.sdrf.txt
Raw data (1)E-GEOD-32657.raw.1.zip
Processed data (1)E-GEOD-32657.processed.1.zip
Array designA-AFFY-149.adf.txt
R ExpressionSetE-GEOD-32657.eSet.r